MYKOL WARNER: Open Payments
NPI 1275158966 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$791 in 42 payments from 15 companies in 2025. Trend: 2023 $1,119 · 2024 $1,311 · 2025 $791
Food & beverage: $791
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $179 |
| ABBVIE INC. | 15 | $158 |
| Axsome Therapeutics, Inc. | 3 | $65 |
| Collegium Pharmaceutical, Inc. | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| Lundbeck LLC | 2 | $50 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $29 |
| Alkermes, Inc. | 1 | $23 |
Products named: CAPLYTA, VRAYLAR, REXULTI, Jornay PM, TRINTELLIX, Auvelity, FANAPT, Qelbree.
Industry payments across CO — which companies pay providers there.
